2022
Optimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at MRI.
Borde T, Nezami N, Laage Gaupp F, Savic LJ, Taddei T, Jaffe A, Strazzabosco M, Lin M, Duran R, Georgiades C, Hong K, Chapiro J. Optimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at MRI. Radiology 2022, 304: 228-237. PMID: 35412368, PMCID: PMC9270683, DOI: 10.1148/radiol.212426.Peer-Reviewed Original ResearchConceptsMedian overall survivalAdvanced-stage hepatocellular carcinomaTransarterial chemoembolizationHepatocellular carcinomaBCLC BBCLC COverall survivalTumor burdenBarcelona Clinic Liver Cancer (BCLC) staging systemLiver Cancer staging systemCancer (AJCC) staging systemConventional transarterial chemoembolizationDrug-eluting beadsAllocation of patientsContrast-enhanced MRIBackground PatientsSurvival benefitRetrospective studyStaging systemC tumorsTumor volumePatientsHeterogeneous patientsMonthsChemoembolization
2020
Therapy of Intermediate-Stage Hepatocellular Carcinoma: Current Evidence and Clinical Practice
Chai N, Chapiro J. Therapy of Intermediate-Stage Hepatocellular Carcinoma: Current Evidence and Clinical Practice. Seminars In Interventional Radiology 2020, 37: 456-465. PMID: 33328701, PMCID: PMC7732559, DOI: 10.1055/s-0040-1719186.Peer-Reviewed Original ResearchIntermediate-stage hepatocellular carcinomaConventional transarterial chemoembolizationHepatocellular carcinomaLocoregional therapyBland embolizationBarcelona Clinic Liver Cancer (BCLC) staging systemImage-guided locoregional therapiesLiver Cancer staging systemDrug-eluting beads TACEIntermediate-stage diseaseLocoregional treatment optionsImmune checkpoint inhibitorsFirst-line therapyCancer (AJCC) staging systemYttrium-90 RadioembolizationClinical evidence pointsThermal ablationNumber of lesionsCheckpoint inhibitorsDEB-TACELocoregional treatmentSelect patientsSurvival benefitTransarterial chemoembolizationClinical evidence
2016
Validation of the Hong Kong Liver Cancer Staging System in Determining Prognosis of the North American Patients Following Intra-arterial Therapy
Sohn JH, Duran R, Zhao Y, Fleckenstein F, Chapiro J, Sahu S, Schernthaner RE, Qian T, Lee H, Zhao L, Hamilton J, Frangakis C, Lin M, Salem R, Geschwind JF. Validation of the Hong Kong Liver Cancer Staging System in Determining Prognosis of the North American Patients Following Intra-arterial Therapy. Clinical Gastroenterology And Hepatology 2016, 15: 746-755.e4. PMID: 27847278, PMCID: PMC5823259, DOI: 10.1016/j.cgh.2016.10.036.Peer-Reviewed Original ResearchConceptsLiver Cancer staging systemIntra-arterial therapyCancer (AJCC) staging systemHong Kong Liver Cancer (HKLC) staging systemStaging systemHepatocellular carcinomaSurvival timeBCLC systemPatient survival timeHKLC systemRetrospective analysisBarcelona Clinic Liver Cancer (BCLC) staging systemStage IVUnresectable hepatocellular carcinomaOverall survival timeKaplan-Meier estimatesDate of deathHepatitis CSystemic chemotherapyHepatitis BMost patientsUnresectable tumorsEntire cohortC-statisticHCC stage